News & Events Press Releases January 13, 2020Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences Media Inquiries To learn more about Kyverna’s work developing cell therapy for inflammatory and autoimmune disease, please reach out to us at: media@kyvernatx.com
